Sangamo Therapeutics Inc. announced the pricing of an underwritten offering that includes 35,190,292 shares of common stock and pre-funded warrants to purchase 17,787,033 shares of common stock, along with accompanying warrants to purchase 52,977,325 shares of common stock. Each share or pre-funded warrant is being sold together with a warrant to purchase one share of common stock. The accompanying warrants have an exercise price of $0.4719 per share, become exercisable six months after issuance, and expire five and a half years from issuance. Additionally, Sangamo has agreed to reduce the exercise price on certain outstanding warrants and extend their term. The gross proceeds from the offering are expected to be approximately $25 million before expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9647823) on February 03, 2026, and is solely responsible for the information contained therein.